Prostatic Urethral Length as a Predictor for Surgery in Benign Prostatic Hyperplasia.


Journal

Journal of Nepal Health Research Council
ISSN: 1999-6217
Titre abrégé: J Nepal Health Res Counc
Pays: Nepal
ID NLM: 101292936

Informations de publication

Date de publication:
10 Mar 2023
Historique:
received: 12 01 2023
accepted: 10 03 2023
medline: 29 3 2023
entrez: 28 3 2023
pubmed: 29 3 2023
Statut: epublish

Résumé

Benign prostatic hyperplasia is associated with structural and morphological changes including elongation of prostatic urethral length. The aim of our study was to assess whether prostatic urethral length could predict need of surgery in patients with benign prostatic hyperplasia. This prospective observational study was conducted over a 12-months duration. All the patients who presented with lower urinary tract symptoms secondary to benign prostatic hyperplasia were evaluated with International Prostate Severity Score, serum Prostate Specific Antigen, Transrectal Ultrasound was done to measure prostatic urethral length, prostate volume, Intravesical prostatic protusion and Post-void Residual Urine. Patients not responding to medical treatment and complications secondary to benign prostatic hyperplasia underwent surgery. Logistic regression analysis was performed to identify risk factors associated with surgery. A total of 153 patients were included in the study. Eighty-three (54.2%) patients underwent surgery during the study period. Prostate volume, intravesical prostatic protrusion, post-void residual volume, serum prostate specific antigen, and prostatic urethral length were significantly higher in the surgical group. The mean prostatic urethral length in the surgical group was 39.47 + 10.2 mm and in the nonsurgical group was 26.20 + 6.72 mm (p <0.0001). According to the ROC curve-based prediction of surgery, the area under the curve for PUL was 0.866 and the best cutoff value was 31.5mm (81% sensitivity and 84.3% specificity). BPH patients with longer PUL may require surgical management. PUL measured by TRUS may be a predicting factor for the need of surgery in BPH Keywords: Benign prostatic hyperplasia; lower urinary tract symptoms; prostatic urethral length.

Sections du résumé

BACKGROUND BACKGROUND
Benign prostatic hyperplasia is associated with structural and morphological changes including elongation of prostatic urethral length. The aim of our study was to assess whether prostatic urethral length could predict need of surgery in patients with benign prostatic hyperplasia.
METHODS METHODS
This prospective observational study was conducted over a 12-months duration. All the patients who presented with lower urinary tract symptoms secondary to benign prostatic hyperplasia were evaluated with International Prostate Severity Score, serum Prostate Specific Antigen, Transrectal Ultrasound was done to measure prostatic urethral length, prostate volume, Intravesical prostatic protusion and Post-void Residual Urine. Patients not responding to medical treatment and complications secondary to benign prostatic hyperplasia underwent surgery. Logistic regression analysis was performed to identify risk factors associated with surgery.
RESULTS RESULTS
A total of 153 patients were included in the study. Eighty-three (54.2%) patients underwent surgery during the study period. Prostate volume, intravesical prostatic protrusion, post-void residual volume, serum prostate specific antigen, and prostatic urethral length were significantly higher in the surgical group. The mean prostatic urethral length in the surgical group was 39.47 + 10.2 mm and in the nonsurgical group was 26.20 + 6.72 mm (p <0.0001). According to the ROC curve-based prediction of surgery, the area under the curve for PUL was 0.866 and the best cutoff value was 31.5mm (81% sensitivity and 84.3% specificity).
CONCLUSIONS CONCLUSIONS
BPH patients with longer PUL may require surgical management. PUL measured by TRUS may be a predicting factor for the need of surgery in BPH Keywords: Benign prostatic hyperplasia; lower urinary tract symptoms; prostatic urethral length.

Identifiants

pubmed: 36974872
doi: 10.33314/jnhrc.v20i3.4613
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

768-773

Auteurs

Surendra Basnet (S)

Department of Urology, National Academy of Medical Sciences, Bir Hospital, Mahaboudha, Kathmandu, Nepal.

Parash Mani Shrestha (PM)

Department of Urology, National Academy of Medical Sciences, Bir Hospital, Mahaboudha, Kathmandu, Nepal.

Anil Shrestha (A)

Department of Urology, National Academy of Medical Sciences, Bir Hospital, Mahaboudha, Kathmandu, Nepal.

Robin Bahadur Basnet (RB)

Department of Urology, National Academy of Medical Sciences, Bir Hospital, Mahaboudha, Kathmandu, Nepal.

Probodh Regmi (P)

Department of Urology, National Academy of Medical Sciences, Bir Hospital, Mahaboudha, Kathmandu, Nepal.

Chitaranjan Shah (C)

Department of Urology, National Academy of Medical Sciences, Bir Hospital, Mahaboudha, Kathmandu, Nepal.

Arvind Kumar Shah (AK)

Department of Urology, National Academy of Medical Sciences, Bir Hospital, Mahaboudha, Kathmandu, Nepal.

Udita Mishra (U)

Department of Urology, National Academy of Medical Sciences, Bir Hospital, Mahaboudha, Kathmandu, Nepal.

Baikuntha Adhikari (B)

Department of Urology, National Academy of Medical Sciences, Bir Hospital, Mahaboudha, Kathmandu, Nepal.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH